Remus Pharmaceuticals Limited - Company Profile

It is a trading public limited company based in Ahmedabad, Gujarat, India, established in 2015.
2015 Ahmedabad, Gujarat, India Active
Last Updated:
Access Report
About Remus Pharmaceuticals Limited

Remus Pharmaceuticals Limited, a active public limited company, was established on 21 September 2015 in Ahmedabad, Gujarat, India. Engaging in wholesale within the trade sector, it holds CIN: L24232GJ2015PLC084536. Registered under ROC Roc Ahmedabad. it is listed. It has an authorized capital of ₹12.50 Cr and a paid-up capital of ₹11.78 Cr.

It upholds a compliant status. In 2023, it reported revenue of ₹46.60 Cr and a net worth of ₹19.14 Cr. Employing 34 professional, Its leadership includes Swapnil Jatinbhai Shah (Director), Anar Swapnil Shah (Director), Roma Vinodbhai Shah (Whole-Time Director). Past directors included Swapnil Jatinbhai Shah, Anar Swapnil Shah, Roma Vinodbhai Shah. It holds ₹15.66 Cr open charges and ₹2.00 Cr settled loans. Its latest AGM occurred on 25 September 2025, with the balance sheet filed on 31 March 2025. It is based at 1101 To 1103, South Tower,One 42,B/H Ashok Vatika, Nr.Jayantilal Park Brts, Ambli Bopal Roa, D, Ahmedabad, Gujarat, 380054.

Company Details
  • Email
    **********
  • Telephone

    +91-XXXXXXXXXX

  • Website
    **********
  • Social Media
    **********
  • Apps
    **********

Company Details

  • CIN/LLPIN

    L24232GJ2015PLC084536

  • Registration Number

    084536

  • Incorporation Date

    21 September 2015

  • Authorized Capital

    ₹12.50 Cr

  • Paid-Up Capital

    ₹11.78 Cr

  • ROC Code

    Roc Ahmedabad

  • Listing Status

    Listed

  • Company Status

    Active

Key Metrics
  • Authorised Capital ₹ 12.50 Cr
  • Paid Up Capital ₹ 11.78 Cr
  • Company Age 10 Year, 6 Months
  • Last Filing with ROC 31 Mar 2025
  • Open Charges ₹ 15.66 Cr
  • Satisfied Charges ₹ 2.00 Cr
  • Revenue Growth **** 83.22%
  • Profit Growth **** 147.60%
  • Ebitda **** 68.22%
  • Net Worth 190.91%
  • Total Assets **** 118.55%
Company report

Remus Pharmaceuticals Limited

Company Report FY 2025-2026

Comprehensive Company Insights

Explore comprehensive insights into Remus Pharmaceuticals Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.

Access Report
Who are the key members and board of directors at Remus Pharmaceuticals Limited?
Current Directors
Name Designation Appointment Date Status
Swapnil Jatinbhai Shah Director 21 Sep 2015 Current
Anar Swapnil Shah Director 30 Dec 2020 Current
Roma Vinodbhai Shah Whole-Time Director 21 Sep 2015 Current
Vishrut Chandramauli Pathak Director 06 Jan 2023 Current
Arpit Deepakkumar Shah Managing Director 21 Sep 2015 Current
Balwant Purohit Director 06 Jan 2023 Current
Past Directors
Name Designation Cessation Status
Pramod Abcsdd Director 23 Feb 2023 Past
Pramod Abcsdd Director 23 Feb 2023 Past
Pramod Abcsdd Director 23 Feb 2023 Past
Pramod Abcsdd Additional Director 28 Feb 2023 Past
Pramod Abcsdd Director 23 Feb 2023 Past
Pramod Abcsdd Additional Director 28 Feb 2023 Past

Discover detailed profiles of directors and KMP - Unlock leadership insights today!

Financial Performance of Remus Pharmaceuticals.

Remus Pharmaceuticals Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 83.22% increase. The company also saw a substantial improvement in profitability, with a 147.6% increase in profit. The company's net worth Soared by an impressive increase of 190.91%.

Remus Pharmaceuticals revenue growth over time
Remus Pharmaceuticals profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors
Emtek
Feb, 2021 Amount Post-IPO - Grab Valuation

investors
Signite Partners
Jan, 2021 Amount Post-IPO - Grab Valuation

investors
Hana Financial Group , GGV Capital
Feb, 2021 Amount Post-IPO - Grab Valuation

investors
Signite Partners
  • Key Matrics
  • Balance Sheet
  • Profit and Loss
  • Cash Flow
  • Ratios
Metrics
(FY 2023) YOY Growth
(FY 2022) (FY 2021) (FY 2020) (FY 2019)
Total Revenue
********
 83.22%
*******
*******
*******
*******
Revenue from Operations
*******
 82.17%
*******
*******
*******
*******
Total Assets
*******
 118.55%
*******
*******
*******
*******
Profit or Loss
*******
 147.60%
*******
*******
*******
*******
Net Worth
*******
 190.91%
*******
*******
*******
*******
EBITDA
*******
 68.22%
*******
*******
*******
*******

Discover detailed financial data and - Unlock financial today!

What is the Ownership and Shareholding Structure of Remus Pharmaceuticals?

Unlock access to Remus Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.

Shareholding Pattern (FY 2024)
shareholding
  • Promoters: 92.83%
  • Public: 4.10%
  • Others: 3.07%
Shareholding Pattern over the Year
FY (2024) FY (2023) FY (2022) FY (2021) FY (2020)
Promoters 92.83 94.62 94.55 94.55 94.55
Public 4.10 3.89 3.95 3.96 3.98
Others 3.07 1.49 1.50 1.49 1.47

Reveal ownership structures and financial performance - Get instant access now!

Charges (Loans)
Open Charges

₹156,632,000.00

Satisfied Charges

₹20,000,000.00

Charges Breakdown by Lending Institutions
  • Hdfc Bank Limited : 15.16 Cr
  • Others : 0.50 Cr
Latest Charge Details
Date Lender Amount Status
27 Oct 2025 Others ₹4.99 M Open
26 Sep 2025 Hdfc Bank Limited ₹10.48 Cr Open
26 Jun 2025 Hdfc Bank Limited ₹2.19 Cr Open
02 Sep 2024 Hdfc Bank Limited ₹1.00 Cr Open
26 Feb 2024 Hdfc Bank Limited ₹1.50 Cr Open

Explore comprehensive loan charge details -

How Many Employees Work at Remus Pharmaceuticals?

Remus Pharmaceuticals has a workforce of 34 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.

Employee Date Number of Employees
2020 78,000
2021 80,500
2022 83,200
2023 86,000
2024 89,500
2025 92,000
Deals i
Graph showing company valuation over time

Gain comprehensive insights into the Deals and Valuation data of Remus Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Remus Pharmaceuticals's trajectory.

Rating
Graph displaying rating trends over time

Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.

Alerts
Alert Indicator

Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.

Explore deal ratings and alerts - Get instant access now!

Latest Updates, News, and FAQs on Remus Pharmaceuticals
Recent Activity within the Organization
  • Charges

    Progress on A charge with Others amounted to Rs. 0.50 Cr with Charge ID 101188093 was registered on 27 Oct 2025. was documented.

  • Charges

    Progress on A charge with Hdfc Bank Limited amounted to Rs. 10.48 Cr with Charge ID 101185694 was registered on 26 Sep 2025. was documented.

  • Annual General Meeting

    Progress on Remus Pharmaceuticals Limited last Annual general meeting of members was held on 25 Sep 2025 as per latest MCA records. was documented.

  • Charges

    The activity A charge with Hdfc Bank Limited amounted to Rs. 2.19 Cr with Charge ID 101117662 was registered on 26 Jun 2025. was completed.

  • Balance Sheet

    Progress on Remus Pharmaceuticals Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Ahmedabad. was documented.

  • Charges

    The activity A charge with Hdfc Bank Limited amounted to Rs. 1.00 Cr with Charge ID 100969089 was registered on 02 Sep 2024. was completed.

Explore recent activity and updates - View Recent Activity

Frequently Asked Questions
What is the CIN of Remus Pharmaceuticals Limited?

The CIN of Remus Pharmaceuticals Limited is L24232GJ2015PLC084536.

Where is Remus Pharmaceuticals Limited headquartered?

Remus Pharmaceuticals Limited is headquartered at 1101 To 1103, South Tower,One 42,B/H Ashok Vatika, Nr.Jayantilal Park Brts, Ambli Bopal Roa, D, Ahmedabad, Gujarat, 380054.

When was Remus Pharmaceuticals Limited incorporated?

Remus Pharmaceuticals Limited was incorporated on 21 September 2015.

Who are the current directors of Remus Pharmaceuticals Limited?

The current directors of Remus Pharmaceuticals Limited are

What is the primary industry of Remus Pharmaceuticals Limited?

The primary industry of Remus Pharmaceuticals Limited is Trade.

Is Remus Pharmaceuticals Limited a listed company?

Remus Pharmaceuticals Limited is listed.

What is the capital structure of Remus Pharmaceuticals Limited?

The authorized capital of Remus Pharmaceuticals Limited is ₹12.50 Cr, and the paid-up capital is ₹11.78 Cr.

What is the compliance status of Remus Pharmaceuticals Limited?

The compliance status of Remus Pharmaceuticals Limited is Compliant.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available